doxorubicin hydrochloride / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   643 Trials   643 Trials   26774 News 


«12...470471472473474475476477478479480...522523»
  • ||||||||||  bortezomib / Generic mfg., melphalan / Generic mfg., thalidomide / Generic mfg.
    Trial primary completion date:  UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy (clinicaltrials.gov) -  Sep 6, 2017   
    P3,  N=177, Active, not recruiting, 
    Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Aug 2017 --> Aug 2018
  • ||||||||||  Trial primary completion date:  Acupuncture Prevents Chemobrain in Breast Cancer Patients (clinicaltrials.gov) -  Sep 6, 2017   
    P=N/A,  N=168, Recruiting, 
    Trial primary completion date: Aug 2017 --> Aug 2018 Trial primary completion date: Jul 2017 --> Oct 2018
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal:  Recurrent Meningioma of the Cervical Spine, Successfully Treated with Liposomal Doxorubicin. (Pubmed Central) -  Sep 5, 2017   
    Our patient, a 35-year-old man with recurrent meningioma compressing the cervical spinal cord received liposomal doxorubicin for 22 months with clinical improvement, minimal toxicity, and slow regression of his tumor. He is well and without progression 18 months after stopping chemotherapy and 4 years after his last progression event.
  • ||||||||||  Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
    Trial primary completion date:  Erythropoietin for Management of Anemia Caused by Chemotherapy (clinicaltrials.gov) -  Sep 1, 2017   
    P2,  N=53, Active, not recruiting, 
    He is well and without progression 18 months after stopping chemotherapy and 4 years after his last progression event. Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Enrollment change, Trial withdrawal, Trial primary completion date:  Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma (clinicaltrials.gov) -  Aug 31, 2017   
    P=N/A,  N=0, Withdrawn, 
    Trial primary completion date: Dec 2016 --> Dec 2017 N=238 --> 0 | Terminated --> Withdrawn | Trial primary completion date: Dec 2016 --> Mar 2014
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Journal:  Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. (Pubmed Central) -  Aug 31, 2017   
    In addition, patients treated with R-CHOP experienced inferior 3-year RFS compared with those who received intensive front-line therapy. When considered in conjunction with reports of patients with newly diagnosed DHL, which demonstrate lower rates of disease response to R-CHOP compared with intensive front-line therapy, our findings further support the use of intensive front-line therapy for this patient population.
  • ||||||||||  Adcetris (brentuximab vedotin) / Takeda, Pfizer
    Trial primary completion date:  Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma (clinicaltrials.gov) -  Aug 30, 2017   
    P2,  N=34, Active, not recruiting, 
    When considered in conjunction with reports of patients with newly diagnosed DHL, which demonstrate lower rates of disease response to R-CHOP compared with intensive front-line therapy, our findings further support the use of intensive front-line therapy for this patient population. Trial primary completion date: Jan 2017 --> Jan 2015
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal:  A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). (Pubmed Central) -  Aug 30, 2017   
    Standard dose P can be safely combined with G, G+NP, G+V, I and LD. Efficacy was observed in multiple tumour types and evaluation to determine if response and duration of response are more robust than what would be expected for chemotherapy or immunotherapy alone requires further validation.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Enrollment closed, Trial primary completion date:  Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma (clinicaltrials.gov) -  Aug 29, 2017   
    P2,  N=33, Active, not recruiting, 
    Trial primary completion date: May 2017 --> May 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> Aug 2019
  • ||||||||||  Rituxan (rituximab) / Roche
    Trial completion, Trial primary completion date, IO biomarker, Metastases:  Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients (clinicaltrials.gov) -  Aug 28, 2017   
    P3,  N=210, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2018 --> Aug 2017
  • ||||||||||  Trial termination, Trial primary completion date:  Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer (clinicaltrials.gov) -  Aug 24, 2017   
    P2,  N=30, Terminated, 
    These results indicate that alectinib may be a promising therapeutic agent for the treatment of NB. Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Aug 2016; Enrollment Completed
  • ||||||||||  Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
    Enrollment open, Trial initiation date, Trial primary completion date, Metastases:  Trabectedin Maintenance Post 1st-line in STS (clinicaltrials.gov) -  Aug 24, 2017   
    P3,  N=90, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2018 --> Jun 2018 Not yet recruiting --> Recruiting | Initiation date: Apr 2017 --> Aug 2017 | Trial primary completion date: Apr 2019 --> Aug 2019
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, pomalidomide / Generic mfg.
    Journal:  Kaposi sarcoma herpesvirus-associated disorders and related diseases. (Pubmed Central) -  Aug 23, 2017   
    KSHV is the etiological agents of all forms of Kaposi sarcoma and several other diseases. Strategies employing immunomodulatory agents, cytokine inhibition, and targeting of KSHV-infected cells are areas of active research.
  • ||||||||||  prednisone / Generic mfg., doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg.
    Journal:  Angioimmunoblastic T-cell lymphoma: the many faced lymphoma. (Pubmed Central) -  Aug 23, 2017   
    The treatment of relapsed or refractory AITL remains an unmet need. The spectrum of AITL from diagnosis to treatment is reviewed below in a fashion that may one day lead to personalized treatment approach in a many faced disease.
  • ||||||||||  Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Enrollment open:  Chidamide With R-CHOP Regimen for DLBCL Patients (clinicaltrials.gov) -  Aug 22, 2017   
    P2,  N=39, Recruiting, 
    Recruiting --> Suspended Not yet recruiting --> Recruiting
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Biomarker, Journal:  Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer. (Pubmed Central) -  Aug 18, 2017   
    In breast cancer patients undergoing doxorubicin therapy, early alterations in arginine-NO metabolite levels occurred, and early biomarker changes were associated with a greater CTRCD rate. Our findings highlight the potential mechanistic and translational relevance of this pathway to CTRCD.
  • ||||||||||  oxaliplatin / Generic mfg., cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Trial completion, Trial primary completion date:  Treating Peritoneal Carcinomatosis With PIPAC (clinicaltrials.gov) -  Aug 16, 2017   
    P2,  N=35, Completed, 
    Cancer 2017;123:1810-1816. Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Aug 2017